Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B) - Chan, Henry L.Y.; Ahn, Sang Hoon; Chang, Ting-Tsung; Peng, Cheng-Yuan; Wong, David; Coffin, Carla S.; Lim, Seng Gee; Chen, Pei-Jer; Janssen, Harry L.A.; Marcellin, Patrick; Serfaty, Lawrence; Zeuzem, Stefan; et al. (Journal of hepatology, 2016)
Keywords: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Gastroenterology and Hepatology; Hepatitis B e Antigens - immunology; Hepatitis B virus - immunology; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - immunology; Hepatitis B, Chronic - virology; Human; Humans; Immunomodulatory therapy; Interleukins - administration & dosage; Male; Polyethylene Glycols - administration & dosage; Time Factors; Treatment Outcome; Viral hepatitis; LLOQ; 80% CIs; qHBsAg; pegIFN-alfa; qHBeAg; alfa; mITT; IFN; lambda; Viral hepatitis; SNP; ULN; Immunomodulatory therapy; TLR; ISG; Human; Hgb; AE; HBeAg; HBsAg; HBsAb; NA; LLOD; SAE; HBeAb; CHB; NK; CHC; quantitative hepatitis B e antigen; single nucleotide polymorphism; 80% confidence intervals; natural killer; hepatitis B e antibody; lower limit of quantification; quantitative hepatitis B surface antigen; chronic hepatitis B; nucleos(t)ide analogue; chronic hepatitis C; adverse event; lower limit of detection; modified intent-to-treat; hemoglobin; peginterferon alfa-2a; peginterferon lambda-1a; serious adverse event; HBeAg-positive; HBsAg-positive; interferon; hepatitis B surface antibody; pegylated interferon alfa; upper limit of normal; toll-like receptor; IFN-stimulated gene